Quest Diagnostics Incorporated (DGX)

Return on equity (ROE)

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (ttm) US$ in thousands 871,000 841,000 840,000 846,000 854,000 763,000 792,000 790,000 942,000 1,230,000 1,479,000 1,874,000 1,988,000 2,175,000 2,238,000 1,794,000 1,425,000 1,102,000 750,000 772,000
Total stockholders’ equity US$ in thousands 6,778,000 6,809,000 6,617,000 6,432,000 6,307,000 6,425,000 6,249,000 6,050,000 5,893,000 6,235,000 6,411,000 6,377,000 6,444,000 6,392,000 5,899,000 6,745,000 6,759,000 6,400,000 5,831,000 5,657,000
ROE 12.85% 12.35% 12.69% 13.15% 13.54% 11.88% 12.67% 13.06% 15.99% 19.73% 23.07% 29.39% 30.85% 34.03% 37.94% 26.60% 21.08% 17.22% 12.86% 13.65%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $871,000K ÷ $6,778,000K
= 12.85%

Quest Diagnostics Incorporated has shown fluctuation in its return on equity (ROE) over the period from March 31, 2020, to December 31, 2024. The ROE started at 13.65% in March 2020 and saw a slight decrease to 12.86% by June 2020. However, there was a significant improvement as the ROE reached 21.08% by December 2020. The positive trend continued into 2021, with ROE hitting 37.94% by June 2021, showing strong performance.

Subsequently, the ROE decreased to 12.69% by June 2024, indicating a decline in profitability compared to the peak observed in 2021. However, the ROE remained relatively stable around the 12-13% range in the following periods up to December 2024.

Overall, Quest Diagnostics Incorporated experienced fluctuations in its ROE, exhibiting both strong and weaker periods of profitability. It is essential for stakeholders to monitor these changes closely to understand the company's performance and future potential.